Corteva delivered a strong performance in 2025, achieving record operating EBITDA of $3.85 billion, up 14% year-over-year, with organic sales growing 4% and operating margins expanding over 215 basis points to exceed 22%. Free cash flow surged to $2.9 billion, an increase of $1.2 billion, driven by operational discipline and working capital improvements, enabling approximately $1.5 billion in shareholder returns. For 2026, the company reiterated guidance for operating EBITDA of $4.0 to $4.2 billion (7% growth at the midpoint) and EPS of $3.45 to $3.70, supported by a transformative resolution with Bayer that accelerates licensing opportunities and achieves royalty neutrality two years ahead of schedule. Despite 'less than ideal' market conditions in Crop Protection, management remains confident, citing robust demand for differentiated technologies and a clear path to the separation of SpinCo in the fourth quarter of 2026.
| Metric | Value | Change |
|---|---|---|
| FY 2025 Operating EBITDA | $3.85 billion | +14% year-over-year |
| FY 2025 Operating EBITDA Margin | >22% | +215 basis points year-over-year |
| FY 2025 Free Cash Flow | $2.9 billion | +$1.2 billion year-over-year |
| FY 2025 Organic Sales Growth | 4% | Up 4% year-over-year |
| FY 2025 Net Cost Improvements | $650 million | Productivity and cost benefits |
| 2026 Operating EBITDA Guidance | $4.0 - $4.2 billion | +7% growth at midpoint |
| 2026 EPS Guidance | $3.45 - $3.70 per share | +7% growth at midpoint |
| 2026 Net Royney Improvement | $120 million | Achieving royalty neutrality |
The comprehensive resolution with Bayer represents a major strategic pivot, removing litigation overhang and significantly accelerating Corteva's licensing ambitions. By paying $610 million, Corteva secured freedom to operate, accelerating the introduction of proprietary triple-stack corn technologies to 2027 (5 years early) and entering the cotton licensing market. Management estimates this agreement will generate $1 billion in aggregate earnings upside over the next decade and achieves 'royalty neutrality' in 2026, two years ahead of schedule.
The separation of SpinCo remains on track for the fourth quarter of 2026, with a CEO announcement expected in the first half and an Investor Day planned for mid-September. Management emphasized 'one team until we're not,' indicating a focus on operational continuity during the transition. The separation is viewed as a mechanism to sharpen focus and unlock value, with $50 million of net dissynergies already factored into the 2026 guidance.
Corteva is successfully pivoting its Brazil Seed strategy from a vertically integrated model to a pure licensing and multiplier model. Following the transition to 100% licensing for Conkesta E3 soybeans, the company expects to double its market share in 2026 to the 'mid-teens plus,' driven by new genetic platforms and strong demand. This shift is a key driver of the expected $120 million improvement in net royalty expense for 2026.
Innovation in Crop Protection, specifically biologicals and new modes of action, is proving resilient against competitive pricing pressures. Management highlighted double-digit volume growth in biologicals and strong demand for new products, which are expected to drive mid-single-digit volume growth in 2026 despite a 'less than ideal' pricing environment. This underscores the success of their strategy to differentiate the portfolio away from commoditized chemistry.
Gene editing is emerging as a critical growth vector, supported by progressing regulatory frameworks globally. Management noted positive developments in the EU regarding a science-based framework and highlighted the upcoming commercialization of a multi-disease resistant (MDR) corn hybrid in the U.S. within 1-2 years of regulatory approval. This technology is viewed as essential for improving farmer profitability amidst thin margins.
The Crop Protection market continues to face structural headwinds, particularly in Latin America and Asia Pacific, where 'competitive pricing dynamics' and 'ample supply' of generics are pressuring margins. Management admitted that pricing in Brazil is expected to remain under pressure in 2026, and while they expect modest market growth, the environment remains volatile and dependent on Chinese export policies.
Free cash flow in 2026 is expected to normalize lower than the record $2.9 billion achieved in 2025. CFO David Johnson warned that 2025 benefited from favorable working capital dynamics (300-400 bps lower than typical) and a favorable cash credit mix that may not repeat. Additionally, 2026 will absorb the $610 million Bayer payment and separation costs, constraining cash available for shareholder returns.
Farmer financial health, particularly in Latin America, remains a concern. High interest rates and suppressed commodity prices are creating 'tight' cash flow for farmers, potentially impacting their purchasing decisions. While Corteva is utilizing barter programs (nearly $1 billion in revenue) to mitigate risk, a prolonged period of farmer stress could impact demand for premium Tier C technologies.
Tariffs present a tangible financial headwind for 2026, estimated at approximately $80 million, primarily impacting Crop Protection actives imported from China into the United States. While management has built this into guidance, the escalation of trade barriers remains a risk factor that could compress margins if not offset by further productivity savings.
Overall: Management exhibited a high degree of confidence and discipline throughout the call, characterizing 2025 as a 'record year' and expressing strong optimism for 2026 despite acknowledging 'less than ideal' market conditions in Crop Protection. Executives were particularly enthusiastic about the Bayer agreement, framing it as a strategic 'win' that unlocks significant value, while maintaining a pragmatic, 'controlling the controllables' approach regarding the upcoming corporate separation.
Confidence: HIGH - Management provided specific quantitative guidance, detailed the mechanics of the Bayer deal with precision, and confidently reiterated 2026 targets early in the year. The tone was decisive regarding the separation timeline and the acceleration of their licensing business.
Management expects operating EBITDA to be in the range of $4.0 billion to $4.2 billion, representing approximately 7% growth at the midpoint ($4.1 billion). This includes a $120 million improvement in net royalty expense, $200 million in productivity savings, and a $75 million currency tailwind, partially offset by an $80 million tariff headwind and $50 million in net dissynergies.
Operating EPS is projected to be between $3.45 and $3.70 per share, an increase of 7% at the midpoint. This growth reflects higher earnings and a lower average share count, partially offset by higher net interest expense.
Free cash flow is expected to be impacted by separation costs and the $610 million Bayer agreement payment. Absent these items, management stated FCF would be in line with their long-term target (45-50% conversion), though working capital is expected to normalize from the exceptionally low levels seen in 2025.
The company expects organic sales growth driven by a mid-single-digit increase in Crop Protection volumes and flat Seed volumes (impacted by a shift from corn to soy acres). Pricing is expected to be slightly up overall, with gains in Seed offset by declines in Crop Protection.
Hedging & Uncertainty: Management generally used direct and confident language, particularly regarding the Bayer agreement and 2026 guidance, using phrases like 'we remain on track' and 'we feel good.' However, hedging was present when discussing external market factors, using qualifiers such as 'less than ideal market conditions,' 'logical to assume,' and 'modest growth' regarding the Crop Protection outlook. They also tempered expectations on free cash flow conversion by noting 2025 was a high-water mark and 2026 would be 'absent any type of onetime items' in line with targets, effectively hedging against a year-over-year decline.
We are one team until we're not. - Charles Magro, CEO
Controlling the controllables. - Charles Magro, CEO
It's still quite early in the year with winter still firmly in place but we feel good about how 2026 is shaping up. - Charles Magro, CEO
We consider this resolution to be a win for our long-term strategic objectives. - Charles Magro, CEO
Absent these [separation items], we would be in line with our long-term target. - David Johnson, CFO
Farmers continue to prioritize top Tier C technologies while managing tighter margins. - Charles Magro, CEO
We're expecting to cross double-digit trade penetration for Conkesta this year in Brazil. - Charles Magro, CEO
Analyst Sentiment: Analysts were highly engaged and focused on the strategic implications of the Bayer agreement, asking detailed questions about the acceleration of product timelines and the financial mechanics of the royalty savings. There was also significant interest in the specific mechanics of the Brazil soybean business transition and the sustainability of Crop Protection margins amidst pricing pressure. The tone was inquisitive but generally constructive.
Management Responses: Management responses were detailed and transparent, particularly from CEO Chuck Magro and CFO David Johnson regarding the Bayer deal. They provided specific timelines (e.g., 2027 for corn licensing) and financial breakdowns ($1 billion upside). When pressed on guidance conservatism or market share specifics, executives remained disciplined, reiterating the 'controlling the controllables' philosophy and pointing to the early stage of the season as a reason for not getting more specific on acreage shifts.
Bayer Agreement Mechanics: Analysts sought clarity on the $610 million payment, the elimination of future royalties, and the acceleration of corn/cotton licensing. Management clarified that the payment resolves litigation and accelerates licensing income by 5 years, creating a $1 billion opportunity.
Brazil Soybean Strategy: Questions focused on the shift to a 100% licensing model for Conkesta E3. Management confirmed the transition is complete and expects market share to double to 'mid-teens plus' in 2026, driving significant earnings growth.
Crop Protection Pricing & Tariffs: Analysts inquired about the sustainability of pricing power in Latin America and the impact of tariffs. Management acknowledged ongoing pressure but emphasized the strength of their differentiated portfolio (2/3 of sales) and confirmed the $80 million tariff headwind is largely China-related.
Free Cash Flow Conversion: Analysts asked if the record 2025 FCF was repeatable. Management clarified that 2025 benefited from working capital tailwinds and that 2026 would see a normalization, though they remain committed to capital allocation including $500 million in buybacks in H1.
Corteva presents a compelling investment case driven by the successful resolution of the Bayer litigation, which serves as a major catalyst by unlocking licensing revenue and removing legal overhang. The company demonstrated strong operational resilience in 2025, delivering record margins and free cash flow despite a challenging macro environment, proving the effectiveness of its 'controlling the controllables' strategy. The 2026 guidance for 7% EBITDA growth appears conservative, particularly given the acceleration of royalty neutrality and the ramp-up of the Brazilian soybean licensing business. Key success factors include the execution of the SpinCo separation without operational disruption and the continued share gains in North American corn and Brazilian soybeans. Risks are largely external, including persistent pricing pressure in Crop Protection and farmer financial stress in Latin America, but these are mitigated by Corteva's shift toward higher-margin differentiated technologies and biologicals. With a clear path to separation, a robust innovation pipeline in gene editing, and a capital allocation strategy focused on returning cash to shareholders, Corteva offers a balanced risk-reward profile suitable for a Buy rating.
Global farmer economics remain under pressure, characterized by 'tighter margins' and high interest rates, particularly in Latin America. Management noted that while demand for food and fuel is at record levels, farmers are prioritizing 'top Tier C technologies' to maximize efficiency, suggesting a trade-down in some input categories but a resilience in demand for high-yield traits. This indicates a bifurcated agricultural market where premium technology is insulated while generic inputs face pricing pressure.
The Crop Protection industry is experiencing a 'well-supplied market' driven by imports from China, leading to aggressive 'competitive pricing dynamics' in regions like Brazil and Asia Pacific. Management noted that China may be taking steps to control exports (repealing export VAT), which could eventually stabilize prices, but the current environment is characterized by an oversupply of generic molecules pressuring margins across the sector.
The regulatory landscape for gene editing is improving globally, with the EU moving towards a 'science-based' framework and most major producing countries establishing policies. This is a critical macro development for the seed industry, as it opens up significant market opportunities for differentiated products like Corteva's multi-disease resistant corn, potentially accelerating the replacement of conventional seeds with higher-value, gene-edited alternatives.